Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

Presentation TCT 2025

TCT 488: Sex-Based Differences in Cardiovascular Outcomes With Achieved LDL-C <55 mg/dL: A Comparative Cohort Analysis

Presenter: Mehmet Cilingiroglu

October 28, 2025

Presentation TCT 2025

Optimizing PCI Outcomes After ACS: Lipid Modification Therapies - LDL, Lp(a) and Beyond

Presenter: Marc P. Bonaca

October 27, 2025

Presentation TCT 2025

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

TCT 470: Comparative Outcomes of Serum LDL Levels <55 mg/dL Versus 55–100 mg/dL for Primary Prevention of Undiagnosed Coronary Artery Disease: A Retrospective Cohort Study

Presenter: Mehmet Cilingiroglu

October 27, 2025

Presentation TCT 2025

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

ACS Pharma Trials On The Horizon: LDL Lowering Therapies

Presenter: Angelo Oliva

October 26, 2025

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Shelley Wood

September 22, 2022

News Conference News TCT 2022

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

Yael L. Maxwell

September 16, 2022

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Todd Neale

October 21, 2020

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

News Conference News TCT 2018

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

Yael L. Maxwell

September 24, 2018

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

Presentation TCT 2015

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

Presenter: Bernard J. Gersh, Stephen D. Wiviott

October 13, 2015

Presentation TCT 2015

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Evan A. Stein

October 13, 2015

Advertisement

TCT 488: Sex-Based Differences in Cardiovascular Outcomes With Achieved LDL-C <55 mg/dL: A Comparative Cohort Analysis

Optimizing PCI Outcomes After ACS: Lipid Modification Therapies - LDL, Lp(a) and Beyond

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

TCT 470: Comparative Outcomes of Serum LDL Levels <55 mg/dL Versus 55–100 mg/dL for Primary Prevention of Undiagnosed Coronary Artery Disease: A Retrospective Cohort Study

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

ACS Pharma Trials On The Horizon: LDL Lowering Therapies

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content